Biotecnol, Inc

biotecnol is a biotechnology company located in new brunswick, (nj, usa) and in london, (uk), owning the exclusive rights to the tribody platform, a proprietary technology that harbors the potential to generate the next generation of multispecific antibody based therapeutics. tribody molecules are multispecific antibody products that utilize fab fragments to form a scaffold. tribodies are produced with unsurpassed versatility, as they can incorporate up to three different binding domains combining different and novel functions, such as t-cell recruitment and dual tumour targeting, in a single molecule. when developed as cancer therapeutics, the tribodies use anti- cd3 domains, as the effector function to engage t-cells onto the tumor cells to kill them. the tribody technology is protected by granted patents in europe and north america. the company is focusing on developing a proprietary pipeline of products in orphan oncology indications, including a subtype of breast cancer known